MEDICAL SIGNIFICANCE OF NEUROSPICHOPHARMACOLOGY AND THE NECESSITY AND RELEVANCE OF DEVELOPING THIS FIELD

Authors

  • Zafar Isomiddinovich Sanoev, Ibrokhimjon Tuychievich Abdinazarov, Diora Bijanova, Dilshodakhon Begmatjonovna Yo‘ldoshalieva, Guzal Melsovna Ruzmetova, Ozodjon Ilkhamovich Ergashov. Department of pharmacology at TSMU Profi University Faculty of the 3rd General Medican Group 301A at TSMU Eurasian Multidisciplinary University in Tashken Department of Microbiology, Virology, and Immunology at TSMU Author

DOI:

https://doi.org/10.5281/zenodo.20516817

Keywords:

Precision medicine, neuropsychiatric conditions, pharmacogenomics, genetics, gene-environment interactions, bipolar illness, schizophrenia, customized care.

Abstract

The author demonstrates that since the National Institute of Psychiatry and Neurology was shut down, psychiatry has faced challenges, particularly in Hungary. He examines the key elements impeding psychiatry's advancement. He concludes that without a person's holistic approach, which presupposes the biological, mental, cultural-social, and spiritual approaches, the growth of psychiatry is unthinkable. Perceptual disturbances play specific roles in the development of psychopathological symptoms that derive from nervous system function. Despite being only fifty years old, this fact highlights the significance of the neurological system and neuropsychopharmacology, which we have understood since the dawn of time. He focuses on the psychoactive medication that was popular in prehistoric times. He examines a few of them, some of which were the earliest neuropsychopharmacological drugs. He highlights the dichotomy of psychopathological symptoms, which are dependent on the functioning of the nervous system by all means but are partially objective and partially subjective. His remarks guarantee the biological (neurological), psychological, cultural, and spiritual perpetuity while also establishing a new approach to both the individual and psychiatry. They also facilitate the development of psychiatry, the development of a new type of diagnostic system, and the elimination of differences among the experts who deal with people, including neurologists, psychiatrists, psychologists, sociologists, philosophers, and theologians. The biological, genetic, psychic, cultural-social, and spiritual approaches, as well as the use of nanomedicine that makes it possible to identify the organic neurological underpinnings of psychiatric disorders—all of which are critical for future researchers—as well as for the advancement of neuropsychopharmacology based on nervous system function.

References

1.Kalmár S. The importance of neuropsychopharmacology in the development of psychiatry. Neuropsychopharmacol Hung. 2014 Sep;16(3):149-56.

2.Marinković, K. (2019). Neuropsychopharmacology: Recent MEG Investigations. In: Supek, S., Aine, C. (eds) Magnetoencephalography. Springer, Cham. https://doi.org/10.1007/978-3-319-62657-4_42-1

3.Bass JK, Bornemann TH, Burkey M, Chehil S, Chen L, Copeland JR, Eaton WW, Ganju V, Hayward E, Hock RS, Kidwai R, Kolappa K, Lee PT, Minas H, Or F, Raviola GJ, Saraceno B, Patel V (2012) A united nations general assembly special session for mental, neurological, and substance use disorders: the time has come. PLoS Med 9(1):e1001159

4.Bauer M, Kluge C, Bach D, Bradbury D, Heinze HJ, Dolan RJ, Driver J (2012) Cholinergic enhancement of visual attention and neural oscillations in the human brain. Curr Biol 22(5):397–402

5.Milic J, Vucurovic M, Jovic D, Stankovic V, Grego E, Jankovic S, Sapic R. Exploring the Potential of Precision Medicine in Neuropsychiatry: A Commentary on New Insights for Tailored Treatments Based on Genetic, Environmental, and Lifestyle Factors. Genes. 2025; 16(4):371. https://doi.org/10.3390/genes16040371

6.Büki, G.; Hadzsiev, K.; Bene, J. Copy Number Variations in Neuropsychiatric Disorders. Int. J. Mol. Sci. 2023, 24, 13671.

7.Bruzelius, E.; Faghmous, J.H. Precision Population Health. In Encyclopedia of Big Data; Springer International Publishing: Cham, Switzerland, 2022; pp. 757–760.

8.Virolainen, S.J.; VonHandorf, A.; Viel, K.C.M.F.; Weirauch, M.T.; Kottyan, L.C. Gene–environment interactions and their impact on human health. Genes Immun. 2023, 24, 1–11.

9.Wen, K.X.; Milic, J.; El-Khodor, B.; Dhana, K.; Nano, J.; Pulido, T.; Kraja, B.; Zaciragic, A.; Bramer, W.M.; Troup, J.; et al. The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS ONE 2016, 11, e0167201.

10.Strianese, O.; Rizzo, F.; Ciccarelli, M.; Galasso, G.; D’Agostino, Y.; Salvati, A.; Del Giudice, C.; Tesorio, P.; Rusciano, M.R. Precision and personalized medicine: How genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes 2020, 11, 747.

11.Davalos, V.; Esteller, M. Cancer epigenetics in clinical practice. CA Cancer J. Clin. 2023, 73, 376–424. Parikh, D.; Shah, M. A comprehensive study on epigenetic biomarkers in early detection and prognosis of Alzheimer’s disease. Biomed. Anal. 2024, 1, 138–153.

12.Kirkbride, J.B.; Anglin, D.M.; Colman, I.; Dykxhoorn, J.; Jones, P.B.; Patalay, P.; Pitman, A.; Soneson, E.; Steare, T.; Wright, T.; et al. The social determinants of mental health and disorder: Evidence, prevention and recommendations. World Psychiatry 2024, 23, 58–90.

13.Owen, M.J.; Legge, S.E.; Rees, E.; Walters, J.T.R.; O’Donovan, M.C. Genomic findings in schizophrenia and their implications. Mol. Psychiatry 2023, 28, 3638–3647.

14.Cacabelos, R.; Cacabelos, N.; Carril, J.C. The role of pharmacogenomics in adverse drug reactions. Expert Rev. Clin. Pharmacol. 2019, 12, 407–442.

15.McGrath, J.J.; Lim, C.C.W.; Plana-Ripoll, O.; Holtz, Y.; Agerbo, E.; Momen, N.C.; Mortensen, P.B.; Pedersen, C.B.; Abdulmalik, J.; Aguilar-Gaxiola, S.; et al. Comorbidity within mental disorders: A comprehensive analysis based on 145 990 survey respondents from 27 countries. Epidemiol. Psychiatr. Sci. 2020, 29, e153.

16.Manchia, M.; Pisanu, C.; Squassina, A.; Carpiniello, B. Challenges and future prospects of precision medicine in psychiatry. Pharmacogenomics Pers. Med. 2020, 13, 127–140.

17.Van Westrhenen, R.; Aitchison, K.J.; Ingelman-Sundberg, M.; Jukić, M.M. Pharmacogenomics of antidepressant and antipsychotic treatment: How far have we got and where are we going? Front. Psychiatry 2020, 11, 94.

18.Reddy, V.; McCarthy, M.; Raval, A.P. Xenoestrogens impact brain estrogen receptor signaling during the female lifespan: A precursor to neurological disease? Neurobiol. Dis. 2022, 163, 105596.

19.Fathima, T.; Bhat, R. Pharmacogenomics in Psychiatry: Optimizing Psychotropic Drug Therapy-A Comprehensive Review. Int. J. Pharm. Healthc. Innov. 2024, 1, 377–382.

20.Accorroni A, Nencha U, Bègue I. The Interdisciplinary Synergy Between Neurology and Psychiatry: Advancing Brain Health. Clinical and Translational Neuroscience. 2025; 9(1):18. https://doi.org/10.3390/ctn9010018

21.Taslim, S.; Shadmani, S.; Saleem, A.R.; Kumar, A.; Brahma, F.; Blank, N.; Bashir, M.A.; Ansari, D.; Kumari, K.; Tanveer, M.; et al. Neuropsychiatric Disorders: Bridging the Gap Between Neurology and Psychiatry. Cureus 2024, 16, e51655.

22.Ferrari, A.J.; Santomauro, D.F.; Herrera, A.M.M.; Shadid, J.; Ashbaugh, C.; Erskine, H.E.; Charlson, F.J.; Degenhardt, L.; Scott, J.G.; McGrath, J.J.; et al. Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022, 9, 137–150.

23.Steinmetz, J.D.; Seeher, K.M.; Schiess, N.; Nichols, E.; Cao, B.; Servili, C.; Cavallera, V.; Cousin, E.; Hagins, H.; E Moberg, M.; et al. Global, Regional, and National Burden of Disorders Affecting the Nervous System, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024, 23, 344–381.

24.Bassetti, C.L.A.; Heldner, M.R.; Adorjan, K.; Albanese, E.; Allali, G.; Arnold, M.; Bègue, I.; Bochud, M.; Chan, A.; do Cuénod, K.Q.; et al. The Swiss Brain Health Plan 2023–2033.

25.Clin. Transl. Neurosci. 2023, 7, 38. Karadag, N.; Shadrin, A.A.; O’Connell, K.S.; Hindley, G.F.L.; Rahman, Z.; Parker, N.; Bahrami, S.; Fominykh, V.; Cheng, W.; Holen, B.; et al. Identification of Novel Genomic Risk Loci Shared between Common Epilepsies and Psychiatric Disorders. Brain 2023, 146, 3392–3403.

26.Arias, D.; Saxena, S.; Verguet, S. Quantifying the Global Burden of Mental Disorders and Their Economic Value. eClinicalMedicine 2022, 54, 101675.

27.Bassetti, C.L.A.; Endres, M.; Sander, A.; Crean, M.; Subramaniam, S.; Carvalho, V.; Di Liberto, G.; Franco, O.H.; Pijnenburg, Y.; Leonardi, M.; et al. The European Academy of Neurology Brain Health Strategy: One Brain, One Life, One Approach. Eur. J. Neurol. 2022, 29, 2559–2566.

28.Tamborska, A.A.; Jordan, J.T.; Michael, B.D.; Owolabi, M.O. Neurological Advocacy: Empowering the Next Generation of Neurologists. J. Neurol. Sci. 2024, 460, 123014.

Downloads

Published

2026-06-03